Pliant Therapeutics Shares Fall on Drug Trial Pause After Safety Board Review

Dow Jones

02-10

Therapeutics0.00%盤後

By Adriano Marchese

Pliant Therapeutics shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors.

Shares traded 55% lower ahead of the morning bell at $3.51.

The clinical stage biopharmaceutical company said Friday it decided to pause the Beacon-IPF phase 2b trial of bexotegrast after a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board.

The drug is a treatment for idiopathic pulmonary fibrosis, a common type of pulmonary fibrosis which is characterized by scarring of the lungs but in particular, where the scarring is of unknown cause.

The pause means that the company won't enroll anymore patients to the study and will also halt dosing for the time being.

Pliant said that it will review the data to understand the monitoring board's rationale for their recommendation. It has also informed clinical trial investigators and is in the process of informing global regulatory authorities.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

February 10, 2025 06:28 ET (11:28 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

no data

沒有相關數據

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2510535668"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510535668\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2510535668?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510535668","market":"fut","top_or_hot":-1,"title":"Pliant Therapeutics Shares Fall on Drug Trial Pause After Safety Board Review","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors. \n</p>\n<p>\n  Shares traded 55% lower ahead of the morning bell at $3.51. \n</p>\n<p>\n  The clinical stage biopharmaceutical company said Friday it decided to pause the Beacon-IPF phase 2b trial of bexotegrast after a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board. \n</p>\n<p>\n  The drug is a treatment for idiopathic pulmonary fibrosis, a common type of pulmonary fibrosis which is characterized by scarring of the lungs but in particular, where the scarring is of unknown cause. \n</p>\n<p>\n  The pause means that the company won't enroll anymore patients to the study and will also halt dosing for the time being. \n</p>\n<p>\n  Pliant said that it will review the data to understand the monitoring board's rationale for their recommendation. It has also informed clinical trial investigators and is in the process of informing global regulatory authorities. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2025 06:28 ET (11:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pliant Therapeutics Shares Fall on Drug Trial Pause After Safety Board Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPliant Therapeutics Shares Fall on Drug Trial Pause After Safety Board Review\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-02-10 19:28</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors. \n</p>\n<p>\n  Shares traded 55% lower ahead of the morning bell at $3.51. \n</p>\n<p>\n  The clinical stage biopharmaceutical company said Friday it decided to pause the Beacon-IPF phase 2b trial of bexotegrast after a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board. \n</p>\n<p>\n  The drug is a treatment for idiopathic pulmonary fibrosis, a common type of pulmonary fibrosis which is characterized by scarring of the lungs but in particular, where the scarring is of unknown cause. \n</p>\n<p>\n  The pause means that the company won't enroll anymore patients to the study and will also halt dosing for the time being. \n</p>\n<p>\n  Pliant said that it will review the data to understand the monitoring board's rationale for their recommendation. It has also informed clinical trial investigators and is in the process of informing global regulatory authorities. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2025 06:28 ET (11:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2510535668","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510535668","pubTimestamp":1739186880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pliant Therapeutics shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors.Shares traded 55% lower ahead of the morning bell at $3.51.The clinical stage biopharmaceutical company said Friday it decided to pause the Beacon-IPF phase 2b trial of bexotegrast after a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board.The drug is a treatment for idiopathic pulmonary fibrosis, a common type of pulmonary fibrosis which is characterized by scarring of the lungs but in particular, where the scarring is of unknown cause.The pause means that the company won't enroll anymore patients to the study and will also halt dosing for the time being.Pliant said that it will review the data to understand the monitoring board's rationale for their recommendation. It has also informed clinical trial investigators and is in the process of informing global regulatory au","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","PLRX":"Pliant Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"安全委员会审查后药物试验暂停，Pliant Therapeutics股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"PLRX":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Pliant Therapeutics shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors. \n\n\n  Shares traded 55% lower ahead of the morning bell at $3.51. \n\n\n  The clinical stage biopharmaceutical company said Friday it decided to pause the Beacon-IPF phase 2b trial of bexotegrast after a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board. \n\n\n  The drug is a treatment for idiopathic pulmonary fibrosis, a common type of pulmonary fibrosis which is characterized by scarring of the lungs but in particular, where the scarring is of unknown cause. \n\n\n  The pause means that the company won't enroll anymore patients to the study and will also halt dosing for the time being. \n\n\n  Pliant said that it will review the data to understand the monitoring board's rationale for their recommendation. It has also informed clinical trial investigators and is in the process of informing global regulatory authorities. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2025 06:28 ET (11:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}

如果下載按鈕點擊無跳轉，請點擊右上角菜單選擇 “在瀏覽器打開”

立即諮詢
下載APP
掃碼下載APP